RenovoRx, Inc.

NASDAQ:RNXT

Biotechnology

Healthcare
$1.12 -0.86%

-$0.01 today

Market cap
$54.04M
Beta
0.99
P/E (TTM)
-3.4
EPS (TTM)
-$0.32
52W Low $0.70High $1.45

Volume 0.84M

Average 0.29M

RNXT Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

RenovoRx, Inc.NASDAQ: RNXT

Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Financing cash flow declines year over year

Q1 FY2026 financing cash flow of $9.05M fell 16.3% year over year, ahead of the -55.7% change in trailing-twelve-month financing cash flow. Over 3 fiscal years it compounded at +536.8% a year.

Context

  • Financing cash flow amounted to 965.7% of revenue in FY2025, down 34192.4 pp from a year earlier.
  • Financing cash flow increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -16.3% holds above the trailing-twelve-month pace of -55.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$9.05M— QoQ
Last fiscal yearDec 2025
$10.85M-28.3% YoY
LTMMar 2026
$9.08M-55.7% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-16.3%——
1 year-28.3%——
3-year CAGR+536.8%——
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
10.85M USD
Year-over-year change
-28.3%
4-year CAGR
-13.5%

Financing Cash Flow vs competitors

How RNXT compares with its peers on the latest reported figures

  • RNXT's LTM Mar 2026 financing cash flow of $9.08M is the 4th largest of the 6 companies compared; the peer median is $18.52M.
  • Its year-over-year change of -55.7% is the 4th highest of 5, against a peer median of +154.1%.
  • Financing cash flow amounts to 609.9% of revenue for RNXT, versus a peer median of 70.2%.
RNXT Competitors Peer median
Financing Cash Flow for RNXT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MAIAMAIA Biotechnology, Inc.LTM Mar 2026$43.5M +129.9%+12.8%—
CELUCelularity Inc.LTM Dec 2025$18.65M +178.3%-46.2%70.2%
ANVSAnnovis Bio, Inc.LTM Mar 2026$18.52M -56.0%+19474.8%—
RNXTRenovoRx, Inc.LTM Mar 2026$9.08M -55.7%+536.8%609.9%
LTRNLantern Pharma Inc.LTM Mar 2026$1.5M +12391.6%——
PYPDPolyPid Ltd.LTM Dec 2025$0 ———
Peer median (excluding RNXT) $18.52M+154.1%+12.8%70.2%

Competitors are the stored peer set for RNXT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(6.32M)(9.89M)(10.23M)(8.81M)(11.17M)
Depreciation & Amortization9K6K002K
Deferred Income Tax00000
Stock-Based Compensation147K644K1.08M1.17M1.27M
Change in Working Capital(265K)428K605K280K(247K)
Accounts Receivables0000(96K)
Inventory0000(189K)
Accounts Payables363K9K27K25K213K
Other Working Capital(628K)419K578K255K(175K)
Other Non-Cash Items517K0(1.71M)(1.77M)(827K)
Operating Cash Flow(5.92M)(8.81M)(10.26M)(9.13M)(10.97M)
Capital Expenditures(15K)00(12K)(2K)
Acquisitions (Net)00000
Purchases of Investments0(8M)000
Sales of Investments05.97M2.03M00
Other Investing Activities00000
Investing Cash Flow(15K)(2.03M)2.03M(12K)(2K)
Debt Repayment1.98M0000
Common Stock Issued14.56M42K5M15.02M12.1M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities2.79M08K102K(1.3M)
Financing Cash Flow19.33M42K5.01M15.12M10.85M
Effect of Forex Changes00000
Net Change in Cash13.4M(10.8M)(3.22M)5.98M(130K)
Free Cash Flow(5.93M)(8.81M)(10.26M)(9.14M)(10.98M)

RenovoRx, Inc.

NASDAQ:RNXT

Intrinsic Alpha fair value

Locked

Current Price

$1.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.